Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs

The Danish biotech Genmab has made a big splash on the Nasdaq, raising a €450M ($506M) IPO to fuel its antibody drug programs in cancer, autoimmune diseases, and more.

This IPO is one of the biggest in biotech history, behind the whopping €530M Nasdaq entry from US mRNA biotech Moderna last year. It’s also to be expected, coming from the company that developed the blockbuster blood cancer drug Darzalex in partnership with Janssen.

Genmab will use the money to push the development of its antibody drugs. Genmab has many other partnered and proprietary programs ongoing, including developing a preclinical drug with Janssen with the potential to outperform Darzalex in some tumor types.

As well as Janssen, other big companies have Genmab’s drugs in phase III development. Novartis is developing one antibody for the treatment of the neurological disease multiple sclerosis, and Horizon Pharma is developing another for the treatment of thyroid-related eye disease.

With a market cap of over €10B ($11B), Genmab’s position as Europe’s most valuable biotech is secure for the time being. The company has proved popular with investors since the beginning, with a record IPO of €210M on the Copenhagen Stock Exchange back in 2000, just a year after it was founded.


Image from Shutterstock

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.